Skip to main content
OpenTrials
Completed

NCT Number: NCT05326191

First-trimester Placental Ultrasound Study

An observational cohort study to assess the clinical utility of the OxNNet Toolkit for the prediction of adverse pregnancy outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

King's College Hospital NHS, Fetal Medicine Foundation

London, SE5 9RS, United Kingdom

About this study

The First PLUS study is a single centre, prospective, observational study recruiting 4000 women from The Harris Birthright Centre, which provides ultrasound scanning for all women who would attend King's College Hospital NHS Foundation Trust for their pregnancy care.

This study aims to develop a tool to provide reliable measurements of placental size and estimate the blood flow within the placenta during the first trimester of pregnancy. These metrics hope to develop a screening tool for fetal growth restriction (FGR), which is a condition in which a baby fails to grow to its full potential and can cause adverse pregnancy outcomes and is the single most common cause of stillbirth. This devastating outcome could potentially be reduced by stratifying pregnancies into high risk, allowing women to undergo additional monitoring and limiting clinician resource to those in need of it most. Stillbirth is also a serious adverse pregnancy outcome that NHS England is looking to reduce the rate of as part of their long-term plan.

Women 18 years of age or older, attending their first trimester scan during 11-14 weeks of pregnancy, who has a viable pregnancy with no more than one baby with no major defects identified during the scan will be eligible to take part.

The study will take place over 24 months and participants will undergo a single study visit in which their demographics and routine medical history will be recorded, an additional research ultrasound scan will be conducted alongside their routine scan, and blood from a sample taken as part of routine care will be used to assess the level of Placental Growth Factor (PlGF). Participants will then be followed up until the completion of their pregnancy via their pregnancy records (remote follow up) and the outcome of their pregnancy will be recorded.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant
  • 18 years of age, or older
  • Presenting for first-trimester combined test screening between 11+0 and 13+6 weeks of pregnancy
  • Participant is willing and able to give informed consent for participation in the investigation.
  • Able to understand written or verbal English and able to access methods of translation.
  • In the opinion of the investigator, the participant is not at risk or under stress or limited in their ability to participate in the study activities.

Exclusion criteria

  • Participant with a multiple pregnancy (more than one viable fetus) discovered at the scan
  • Participant with a non-viable pregnancy discovered at the scan (no detectable heartbeat)
  • Pregnancies with major defects identified during 11+0 to13+6 week scan
  • Any pregnancy subsequently found to be chromosomally abnormal as a result of either prenatal or postnatal testing

Treatment and study plan

Ultrasound

Diagnostic Test

All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.

Primary outcomes

  1. Fetal Growth restriction (FGR)

    Time frame: 24 months

    Fetal Growth restriction (FGR) defined according to the ISUOG Delphi consensus guidelines for diagnosis of FGR, at the time of delivery.

Secondary outcomes

  1. Small for Gestational Age (GSA)

    Time frame: 24 months

    Defined if <10 centile on population-based centiles or <10th centile on customised centiles, at the time of delivery.

  2. Pre-eclampsia (with, and without, severe features)

    Time frame: 24 months

    Defined by the ACOG guidelines for hypertensive disorders of pregnancy:

    • Pre-term pre-eclampsia (delivery <37 weeks)
    • Late onset pre-eclampsia (delivery ≥37 weeks)
  3. Gestational hypertension (PIH)

    Time frame: 24 months

    Defined by the ACOG guidelines for hypertensive disorders of pregnancy:

    • Pre-term gestational hypertension (delivery <37 weeks)
    • Late onset gestational hypertension (delivery ≥37 weeks)
  4. Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

    Time frame: 24 months

    Defined by the ACOG guidelines for hypertensive disorders of pregnancy:

    • Pre-term HELLP (delivery <37 weeks)
    • Late onset HELLP (delivery ≥37 weeks) Pre-term pre-eclampsia (delivery <37 weeks)
  5. Eclampsia

    Time frame: 24 months

    Defined by the ACOG guidelines for hypertensive disorders of pregnancy(22)

    • Pre-term eclampsia (delivery <37 weeks)
    • Late onset eclampsia (delivery ≥37 weeks)
  6. Gestational diabetes

    Time frame: 24 months

    Defined as fasting plasma glucose level ≥5.6 mmol/L and/or 2-h plasma glucose level ≥7.8 mmol/L after ingestion of 75g oral glucose.

  7. Preterm Birth

    Time frame: 24 months

    Birth ≥24+0 weeks <37+0 weeks

  8. Miscarriage

    Time frame: 24 months

    Live fetus at the first-trimester ultrasound scan but subsequent in utero fetal death or delivery <24+0 weeks

  9. Stillbirth

    Time frame: 24 months

    Baby born with no signs of life at ≥24+0 weeks' gestation

  10. Neonatal death

    Time frame: 24 months

    Baby born alive but dies within the first 28 days of life

  11. Neonatal morbidity

    Time frame: 24 months

    • Neonatal intensive care unit admission and length of stay
    • Neonatal ventilation - defined as need of positive pressure (CPAP, NCPAP or intubation)
    • Respiratory distress syndrome - defined as need of ventilation with or without surfactant
    • Intraventricular haemorrhage (IVH) grade II or above - defined as bleeding into the ventricles
    • Neonatal sepsis confirmed bacteraemia in cultures
    • Anaemia - defined as low haemoglobin and / or haematocrit requiring blood transfusion
    • Necrotizing enterocolitis requiring surgical intervention

Sponsors and collaborators

Lead sponsor

Perspectum

Industry

Collaborators

  • Fetal Medicine Foundation
  • University of Oxford

Registry information

Official study title

First-trimester Placental Ultrasound Study (First PLUS): an Observational Cohort Study to Assess the Clinical Utility of the OxNNet Toolkit for the Prediction of Adverse Pregnancy Outcomes.

Acronym: First PLUS

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Apr 13, 2022
Registry last updated
Dec 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.